Italian antitrust agency investigates Novartis, Biogen and others over Lucentis biosimilar
Italian antitrust authorities are investigating four companies over alleged collusion to delay the introduction of a new biosimilar to Roche’s blockbuster eye drug Lucentis. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.